These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38863718)

  • 1. Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor.
    Zhao J; Wang Q; Tan AF; Loh CJL; Toh HC
    Front Immunol; 2024; 15():1416941. PubMed ID: 38863718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organoids as an Enabler of Precision Immuno-Oncology.
    Zhao J; Fong A; Seow SV; Toh HC
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tumour microenvironment by tyrosine kinase inhibitor.
    Tan HY; Wang N; Lam W; Guo W; Feng Y; Cheng YC
    Mol Cancer; 2018 Feb; 17(1):43. PubMed ID: 29455663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of patient sex on the efficacy and safety of anticancer immunotherapy.
    Pala L; Conforti F
    Expert Opin Drug Saf; 2021 Dec; 20(12):1535-1544. PubMed ID: 34468257
    [No Abstract]   [Full Text] [Related]  

  • 5. Androgen receptor-mediated CD8
    Yang C; Jin J; Yang Y; Sun H; Wu L; Shen M; Hong X; Li W; Lu L; Cao D; Wang X; Sun J; Ye Y; Su B; Deng L
    Immunity; 2022 Jul; 55(7):1268-1283.e9. PubMed ID: 35700739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCRK is a novel signalling hub exploitable in cancer immunotherapy.
    Mok MT; Zhou J; Tang W; Zeng X; Oliver AW; Ward SE; Cheng AS
    Pharmacol Ther; 2018 Jun; 186():138-151. PubMed ID: 29360538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex differences in renal cell carcinoma: a single-cell analysis reveals exhausted CD8
    Ning K; Peng Y; Jiang Y; Li Z; Luo X; Lin L; Deng M; Wu Y; Huang T; Huang Y; Xie Y; Yang X; Zhang M; Xiong L; Zou X; Zhou Z; Zhou F; Dong P; Yu C; Zhang Z
    Biol Sex Differ; 2023 Sep; 14(1):58. PubMed ID: 37715192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular adaptor molecules and AR signalling in the tumour microenvironment.
    Reebye V; Frilling A; Habib NA; Mintz PJ
    Cell Signal; 2011 Jun; 23(6):1017-21. PubMed ID: 21130868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor moonlighting in the prostate cancer microenvironment.
    Cioni B; Zwart W; Bergman AM
    Endocr Relat Cancer; 2018 Jun; 25(6):R331-R349. PubMed ID: 29618577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic immunity in cancer.
    Hiam-Galvez KJ; Allen BM; Spitzer MH
    Nat Rev Cancer; 2021 Jun; 21(6):345-359. PubMed ID: 33837297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications.
    Xiao T; Lee J; Gauntner TD; Velegraki M; Lathia JD; Li Z
    Nat Rev Cancer; 2024 May; 24(5):338-355. PubMed ID: 38589557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
    Yang L; Li A; Lei Q; Zhang Y
    J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression.
    Armitage JD; Newnes HV; McDonnell A; Bosco A; Waithman J
    Cells; 2021 Jan; 10(1):. PubMed ID: 33401460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgens and esophageal cancer: What do we know?
    Sukocheva OA; Li B; Due SL; Hussey DJ; Watson DI
    World J Gastroenterol; 2015 May; 21(20):6146-56. PubMed ID: 26034350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cancer-related inflammation in the era of immunotherapy.
    Nakamura K; Smyth MJ
    Immunol Cell Biol; 2017 Apr; 95(4):325-332. PubMed ID: 27999432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Repolarisation of Tumour-Associated Macrophages.
    van Dalen FJ; van Stevendaal MHME; Fennemann FL; Verdoes M; Ilina O
    Molecules; 2018 Dec; 24(1):. PubMed ID: 30577495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.